Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 9, 9, 34, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 7 molecules, respectively.

Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acurx Pharmaceuticals Inc
Adiso Therapeutics Inc
Affinivax Inc
Appili Therapeutics Inc
Ascendo Biotechnology Inc
Biomica
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Cambimune Ltd
Chain Biotechnology Ltd
Crestone Inc
CSA Biotechnologies LLC
Daiichi Sankyo Co Ltd
Deinove SAS
Destiny Pharma Plc
Enterobiotix Ltd
Facile Therapeutics Inc
Finch Therapeutics Group Inc
First Wave BioPharma Inc
Fzata Inc
Gateway Pharmaceutical LLC
GSK plc
Idorsia Pharmaceutical Ltd
Immune Biosolutions Inc
ImmuneBiotech AB
ImmuniMed Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
KamTek Inc
Kowa Co Ltd
Lumen Bioscience Inc
Malachite Innovations Inc
Mapp Biopharmaceutical Inc
Matrivax Research & Development Corp
MGB Biopharma Ltd
Microbiotica Ltd
Micropharm Ltd
Mikrobiomik Healthcare Company SL
MV BioTherapeutics SA
MyBiotics Pharma Ltd
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Nubiyota LLC
Oragenics Inc
Ostrich Pharma USA Inc
PanTheryx Inc
Pfizer Inc
Proxi Biotech IVS
Pylum Biosciences Inc
Q2 Pharma Ltd
QureTech Bio AB
Rebiotix Inc
Rebus Holdings Inc
Recursion Pharmaceuticals Inc
Sano Chemicals Inc
Scioto Biosciences Inc
Secretory IgA Inc
Seres Therapeutics Inc
Servatus Ltd
Summit Therapeutics Inc
Symbiotic Health Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Vedanta Biosciences Inc
Versatope Therapeutics Inc
Vifor Pharma Ltd
XBiotech Inc
Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Overview

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Companies Involved in Therapeutics Development

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drug Profiles

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Product Development Milestones

Featured News & Press Releases

Jul 07, 2022: Immuron receives European Patent Notification on drug composition to treat clostridioides difficile associated disease

Jun 28, 2022: Vedanta unveils state-of-the-art manufacturing facility to provide clinical and commercial supply of oral therapies based on defined bacterial consortia

Jun 07, 2022: Seres Therapeutics announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection

May 24, 2022: Ferring presents new analyses of efficacy, safety and microbiome composition data at DDW 2022 for RBX2660 its investigational microbiota-based live biotherapeutic

May 22, 2022: Seres Therapeutics presents phase III results of SER-109 for recurrent C. Difficile infection at the Digestive Disease Week (DDW) Annual Meeting

May 19, 2022: Adiso Therapeutics' ADS024 selected for oral presentation at 2022 Digestive Disease Week Annual Meeting

May 12, 2022: Destiny Pharma: World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration

May 10, 2022: Seres Therapeutics to present data on investigational microbiome therapeutic SER-109 for recurrent C. difficile infection at the Digestive Disease Week (DDW) Annual Meeting

Apr 28, 2022: Finch Therapeutics announces removal of FDA clinical hold on CP101 IND

Apr 21, 2022: Adiso Therapeutics announces completion of enrollment in a phase 1b study of ADS024 for the Prevention of C. difficile Recurrence

Apr 18, 2022: Lumen Bioscience announces clinical advancement of LMN-201 for C. difficile Infection

Apr 13, 2022: Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in Cell Host & Microbe nd highlights planned presentations of phase 2 VE303 results

Apr 07, 2022: The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada

Mar 01, 2022: Finch Therapeutics provides an update on its phase 3 trial of CP101 in Recurrent C. difficile Infection

Mar 01, 2022: Phase 3 CLOVER Trial for Pfizer’s investigational Clostridioides Difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, 2022

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.